Allergy Center, An den Quellen 10, D-65183 Wiesbaden, Germany.
Expert Rev Clin Immunol. 2013 May;9(5):465-74; quiz 475. doi: 10.1586/eci.13.25.
Allergic diseases are among the most common diseases in humans. Besides allergen avoidance, allergen-specific immunotherapy is the only causative treatment option. During recent years, many innovations of this therapy have emerged.
Selective literature research in Medline and PubMed, under the inclusion of national and international guidelines and Cochrane meta analyses.
In several meta-analyses, the clinical efficacy of subcutaneous immunotherapy (SCIT) has been largely demonstrated. Recently, major research activities in mucosal immunotherapies focused on the sublingual application route. There are well-documented clinical data on the efficacy and safety of this form of immunotherapy. New application routes as well as new immune-modifying agents such as virus-like particles or CpG-motifs have also been investigated.
SIT is accepted to be the only causative treatment option for allergies. New application routes and new immune-modifying agents will allow for different delivery methods in the future.
过敏性疾病是人类最常见的疾病之一。除了避免过敏原外，过敏原特异性免疫疗法是唯一的病因治疗方法。近年来，这种疗法出现了许多创新。
在 Medline 和 PubMed 中进行选择性文献研究，纳入国家和国际指南以及 Cochrane 荟萃分析。
在几项荟萃分析中，皮下免疫疗法（SCIT）的临床疗效得到了充分证明。最近，黏膜免疫疗法的主要研究活动集中在舌下应用途径上。这种免疫疗法的疗效和安全性有充分的临床数据。新的应用途径以及新型免疫调节剂，如病毒样颗粒或 CpG 基序，也已被研究。
SIT 被认为是过敏的唯一病因治疗方法。新的应用途径和新型免疫调节剂将允许未来采用不同的给药方法。
